RTP Mobile Logo

Regional Meetings 2019

Novel and Emerging Therapeutic Strategies in the Management of Select B-Cell Lymphomas — An Interactive Grand Rounds Series

Research To Practice (RTP) is pleased to offer community- and academic-based hospitals and cancer centers throughout the United States the opportunity to participate in an interactive live educational activity focused on the management of select B-cell lymphomas. Each session in this regional series will feature a blend of didactic presentation, discussion of steering committee members’ treatment recommendations, interactive polling of attendees using keypad devices and follow-up audience Q&A.

If you are interested in hosting a session at your institution, please email our Meeting Services Department at GRTeam@ResearchToPractice.com or call (800) 233-6153.

Learn about our other interactive Grand Rounds CME series:

Event Details

Schedule of Events:

Thursday, October 31, 2019
12:00 PM – 1:00 PM
Education program


Faculty:
John P Leonard, MD
Saint Louis University
St Louis, Missouri

Boxed lunch will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Friday, November 8, 2019
12:00 PM – 1:00 PM
Education program


Faculty:
Andrew M Evens, DO, MSc
Mercy Medical Center
Springfield, Massachusetts

Boxed lunch will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Friday, December 20, 2019
9:00 AM – 10:00 AM
Education program


Faculty:
Andrew M Evens, DO, MSc
Downstate Medical Center SUNY
Brooklyn, New York
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Thursday, January 16, 2020
7:30 AM – 8:30 AM
Education program


Faculty:
Ann S LaCasce, MD, MMSc
Southcoast Centers for Cancer Care
Fairhaven, Massachusetts

Continental breakfast will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Tuesday, January 28, 2020
8:00 AM – 9:00 AM
Education program


Faculty:
John P Leonard, MD
Lenox Hill Hospital
New York, New York

Continental breakfast will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
There is no registration fee for these events. However, preregistration is advised as seating is limited.

Agenda

Each 1-hour session will include 4 topic modules focused on current management, emerging research and novel agents and strategies under active investigation for select lymphomas and chronic lymphocytic leukemia. Each event will employ an identical format that will include the following elements:

  • Discussion of Steering Committee Members’ Treatment Recommendations
  • Review of Available Clinical Research Findings
  • Integration of Interactive Audience Polling Results
MODULE 1 Evolving Treatment Paradigms in the Care of Patients with Chronic Lymphocytic Leukemia MODULE 2 New Agents and Novel Combination Approaches for Patients with Mantle Cell Lymphoma MODULE 3 Chimeric Antigen Receptor T-Cell Therapy MODULE 4 Emerging Treatment Considerations in the Up-Front Management of Advanced Hodgkin Lymphoma

Each session will conclude with a 5-minute Q&A segment

STEERING COMMITTEE MEMBERS

Bruce D Cheson, MD
Professor of Medicine
Deputy Chief, Division of Hematology-Oncology
Head of Hematology
Georgetown University Hospital
Lombardi Comprehensive Cancer Center
Washington, DC

Andrew M Evens, DO, MSc
Associate Director for Clinical Services
Rutgers Cancer Institute of New Jersey
Medical Director, Oncology Service Line
RWJBarnabas Health
Director, Lymphoma Program
Division of Blood Disorders
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Christopher Flowers, MD, MS
Director, Lymphoma Program
Professor of Hematology and Oncology
Bone Marrow and Stem Cell Transplantation
Department of Hematology and Medical Oncology
Winship Cancer Institute
Health Science Research Building
Emory University
Atlanta, Georgia

Ann S LaCasce, MD, MMSc
Program Director, Fellowship in Hematology/Oncology
Associate Professor of Medicine, Harvard Medical School
Institute Physician
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts

John P Leonard, MD
Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Associate Dean for Clinical Research
Weill Cornell Medical College
New York, New York

Julie M Vose, MD, MBA
Neumann M and Mildred E Harris Professor
Chief, Division of Hematology/Oncology
Nebraska Medical Center
Omaha, Nebraska

Andrew D Zelenetz, MD, PhD
Medical Director, Medical Informatics
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Project Chair
Neil Love, MD
President
Research To Practice
Miami, Florida
 

CE Information

Target Audience:
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of select lymphomas and chronic lymphocytic leukemia.

Learning Objectives:

  • Review recent therapeutic advances and related FDA authorizations for patients with mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL) and chronic lymphocytic leukemia (CLL), and use this information to counsel patients regarding protocol and nonresearch therapy.
  • Consider emerging Phase III efficacy and safety data with ibrutinib as a component of first-line therapy for patients with treatment-naïve CLL, and use this information to discern how, if at all, these strategies can be optimally integrated into nonresearch care algorithms.
  • Recall the biologic rationale for and ongoing research evaluating the use of chemotherapy-free combinations in the management of newly diagnosed and progressive CLL and MCL to prepare for the potential introduction of these therapies into practical patient care.
  • Develop an understanding of the biologic rationale for and appreciate available efficacy and safety data with chimeric antigen receptor T-cell therapy, and identify patients with relapsed/refractory B-cell cancers for whom this approach may be appropriate.
  • Describe available and emerging data with other investigational agents and immunotherapeutic strategies currently under evaluation for MCL, DLBCL, HL and CLL, and where applicable, refer eligible patients for trial participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Commercial Support:
These activities are supported by educational grants from AbbVie Inc, Gilead Sciences Inc, Novartis, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Seattle Genetics.